1OT Stock Overview
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ovid Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.88 |
| 52 Week High | US$3.68 |
| 52 Week Low | US$2.46 |
| Beta | 0.69 |
| 1 Month Change | 16.13% |
| 3 Month Change | 1.41% |
| 1 Year Change | 4.35% |
| 3 Year Change | -4.00% |
| 5 Year Change | 67.64% |
| Change since IPO | -75.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1OT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.4% | -4.9% | -1.5% |
| 1Y | 4.3% | -19.9% | 0.9% |
Return vs Industry: 1OT exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 1OT exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| 1OT volatility | |
|---|---|
| 1OT Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1OT's share price has been volatile over the past 3 months.
Volatility Over Time: 1OT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 40 | Jeremy Levin | www.ovidrx.com |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome.
Ovid Therapeutics Inc. Fundamentals Summary
| 1OT fundamental statistics | |
|---|---|
| Market cap | €206.60m |
| Earnings (TTM) | -€49.17m |
| Revenue (TTM) | €368.00k |
579.5x
P/S Ratio-4.3x
P/E RatioIs 1OT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1OT income statement (TTM) | |
|---|---|
| Revenue | US$391.70k |
| Cost of Revenue | US$0 |
| Gross Profit | US$391.70k |
| Other Expenses | US$52.73m |
| Earnings | -US$52.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 100.00% |
| Net Profit Margin | -13,362.17% |
| Debt/Equity Ratio | 0% |
How did 1OT perform over the long term?
See historical performance and comparison